SK284677B6 - Farmaceutický prípravok na liečbu diabetu a spôsob jeho prípravy - Google Patents

Farmaceutický prípravok na liečbu diabetu a spôsob jeho prípravy Download PDF

Info

Publication number: SK284677B6
Authority: SK; Slovakia
Prior art keywords: pancreatin; enzymes; mixture; treatment; patients
Prior art date: 1999-03-17

Application number

SK1285-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK12852001A3 (sk

Inventor

Suntje Sander

Claus Steinborn

Martin Rudmann

Dieter Schwanitz

Friederike Henniges

Original Assignee

Solvay Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-17

Filing date

2000-03-15

Publication date

2005-09-08

2000-03-15 Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh

2002-02-05 Publication of SK12852001A3 publication Critical patent/SK12852001A3/sk

2005-09-08 Publication of SK284677B6 publication Critical patent/SK284677B6/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 48
206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 43
238000004519 manufacturing process Methods 0.000 title claims abstract description 15
238000000034 method Methods 0.000 title claims abstract description 4
239000000825 pharmaceutical preparation Substances 0.000 title abstract description 7
230000008569 process Effects 0.000 title abstract description 3
239000000203 mixture Substances 0.000 claims abstract description 67
102000004190 Enzymes Human genes 0.000 claims abstract description 51
108090000790 Enzymes Proteins 0.000 claims abstract description 51
108010019160 Pancreatin Proteins 0.000 claims abstract description 51
229940088598 enzyme Drugs 0.000 claims abstract description 51
229940055695 pancreatin Drugs 0.000 claims abstract description 51
102000038379 digestive enzymes Human genes 0.000 claims abstract description 30
108091007734 digestive enzymes Proteins 0.000 claims abstract description 30
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 21
230000002797 proteolythic effect Effects 0.000 claims abstract description 21
230000003625 amylolytic effect Effects 0.000 claims abstract description 20
230000002366 lipolytic effect Effects 0.000 claims abstract description 20
241000124008 Mammalia Species 0.000 claims abstract description 4
239000002552 dosage form Substances 0.000 claims abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
102000004882 Lipase Human genes 0.000 claims description 19
108090001060 Lipase Proteins 0.000 claims description 19
239000004367 Lipase Substances 0.000 claims description 19
235000019421 lipase Nutrition 0.000 claims description 19
230000002906 microbiologic effect Effects 0.000 claims description 16
102000013142 Amylases Human genes 0.000 claims description 14
108010065511 Amylases Proteins 0.000 claims description 14
108091005804 Peptidases Proteins 0.000 claims description 14
239000004365 Protease Substances 0.000 claims description 14
235000019418 amylase Nutrition 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 13
239000004382 Amylase Substances 0.000 claims description 10
201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
102000035195 Peptidases Human genes 0.000 claims description 7
229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
229940025131 amylases Drugs 0.000 claims description 4
241001465754 Metazoa Species 0.000 abstract description 7
230000000813 microbial effect Effects 0.000 abstract 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 34
229940068196 placebo Drugs 0.000 description 22
239000000902 placebo Substances 0.000 description 22
102000004877 Insulin Human genes 0.000 description 17
108090001061 Insulin Proteins 0.000 description 17
229940125396 insulin Drugs 0.000 description 17
239000002775 capsule Substances 0.000 description 14
201000010099 disease Diseases 0.000 description 13
230000002641 glycemic effect Effects 0.000 description 12
238000012360 testing method Methods 0.000 description 10
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 9
230000008092 positive effect Effects 0.000 description 8
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
230000006872 improvement Effects 0.000 description 7
239000008188 pellet Substances 0.000 description 7
235000019419 proteases Nutrition 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
239000008103 glucose Substances 0.000 description 6
210000000496 pancreas Anatomy 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 description 5
102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 5
101710099240 Elastase-1 Proteins 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
230000008859 change Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
241000228212 Aspergillus Species 0.000 description 4
208000000668 Chronic Pancreatitis Diseases 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
206010033649 Pancreatitis chronic Diseases 0.000 description 4
108010067035 Pancrelipase Proteins 0.000 description 4
241000235527 Rhizopus Species 0.000 description 4
244000052616 bacterial pathogen Species 0.000 description 4
229940092125 creon Drugs 0.000 description 4
230000006866 deterioration Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000012054 meals Nutrition 0.000 description 4
239000007787 solid Substances 0.000 description 4
206010071394 Hyperglycaemic seizure Diseases 0.000 description 3
206010048803 Hypoglycaemic seizure Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000001079 digestive effect Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
230000003345 hyperglycaemic effect Effects 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000011360 adjunctive therapy Methods 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
238000004362 fungal culture Methods 0.000 description 2
208000020694 gallbladder disease Diseases 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000003319 supportive effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000035467 Pancreatic insufficiency Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010049416 Short-bowel syndrome Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000010030 laminating Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002184 metal Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
235000003715 nutritional status Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000011369 optimal treatment Methods 0.000 description 1
230000004203 pancreatic function Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229940119528 pork insulin Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000011076 safety test Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Enzymes And Modification Thereof (AREA)

SK1285-2001A 1999-03-17 2000-03-15 Farmaceutický prípravok na liečbu diabetu a spôsob jeho prípravy SK284677B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19911778		1999-03-17
PCT/EP2000/002261 WO2000054799A2 (fr)	1999-03-17	2000-03-15	Medicament destine au traitement du diabete

Publications (2)

Publication Number	Publication Date
SK12852001A3 SK12852001A3 (sk)	2002-02-05
SK284677B6 true SK284677B6 (sk)	2005-09-08

Family

ID=7901217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1285-2001A SK284677B6 (sk)	1999-03-17	2000-03-15	Farmaceutický prípravok na liečbu diabetu a spôsob jeho prípravy

Country Status (23)

Country	Link
US (1)	US7122357B2 (fr)
EP (1)	EP1162995B1 (fr)
JP (1)	JP4938174B2 (fr)
CN (1)	CN1221284C (fr)
AT (1)	ATE242003T1 (fr)
AU (1)	AU773930B2 (fr)
BR (1)	BR0009012A (fr)
CA (1)	CA2367355C (fr)
CZ (1)	CZ20013345A3 (fr)
DE (2)	DE10012095A1 (fr)
DK (1)	DK1162995T3 (fr)
ES (1)	ES2194720T3 (fr)
HK (1)	HK1044477B (fr)
HU (1)	HUP0200556A3 (fr)
NO (1)	NO20014507D0 (fr)
NZ (1)	NZ514826A (fr)
PL (1)	PL199180B1 (fr)
PT (1)	PT1162995E (fr)
RU (1)	RU2268065C2 (fr)
SK (1)	SK284677B6 (fr)
TR (1)	TR200102784T2 (fr)
WO (1)	WO2000054799A2 (fr)
ZA (1)	ZA200107110B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1162995B1 (fr) *	1999-03-17	2003-06-04	Solvay Pharmaceuticals GmbH	Enzymes pour le traitement du diabete mellitus de type i
US7020384B1 (en)	1999-08-12	2006-03-28	Lg Electronics Inc.	Method for creating and recording transport time information for data recorded on a disk
US6632429B1 (en)	1999-12-17	2003-10-14	Joan M. Fallon	Methods for treating pervasive development disorders
US20070053895A1 (en) *	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en)	2000-11-16	2011-10-04	Curemark Llc	Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) *	2002-04-25	2012-01-24	Ultraflex Systems, Inc.	Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US7519274B2 (en)	2003-12-08	2009-04-14	Divx, Inc.	File format for multiple track digital data
ES2314646T3 (es)	2004-03-22	2009-03-16	Solvay Pharmaceuticals Gmbh	Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
CA2586222A1 (fr) *	2004-05-24	2005-12-08	Novozymes A/S	Enzymes a vocation pharmaceutique
US20060198838A1 (en) *	2004-09-28	2006-09-07	Fallon Joan M	Combination enzyme for cystic fibrosis
US20090047266A1 (en) *	2005-06-24	2009-02-19	Novozymes A/S	Lipases for Pharmaceutical Use
AU2006261443A1 (en) *	2005-06-24	2006-12-28	Novozymes A/S	Proteases for pharmaceutical use
EP1896057A2 (fr) *	2005-06-24	2008-03-12	Novozymes A/S	Amylases à usage pharmaceutique
HUE031042T2 (en) *	2005-07-29	2017-06-28	Abbott Laboratories Gmbh	Methods for producing pancreatin powder with low viral content
JP5284092B2 (ja) *	2005-08-15	2013-09-11	アボットラボラトリーズゲゼルシャフトミットベシュレンクテルハフツング	腸溶コーティングに適したパンクレアチンマイクロペレットコア
EP1931316B2 (fr)	2005-08-15	2017-02-22	Abbott Laboratories GmbH	Compositions pharmaceutiques a liberation controlee destinees a des medicaments acido-labiles
BRPI0614411A2 (pt) *	2005-08-15	2011-03-29	Solvay Pharm Gmbh	núcleos de micropéletes de pancreatina adequados para revestimento entérico
US9198871B2 (en) *	2005-08-15	2015-12-01	Abbott Products Gmbh	Delayed release pancreatin compositions
US11266607B2 (en)	2005-08-15	2022-03-08	AbbVie Pharmaceuticals GmbH	Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
US20070116695A1 (en) *	2005-09-21	2007-05-24	Fallon Joan M	Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007053619A2 (fr) *	2005-11-01	2007-05-10	Bio-Cat, Inc.	Composition contenant une lipase fongique (levure), et methode permettant de traiter la malabsorption lipidique liee a la mucoviscidose et l'insuffisance pancreatique chez des sujets concernes
US10072256B2 (en)	2006-05-22	2018-09-11	Abbott Products Gmbh	Process for separating and determining the viral load in a pancreatin sample
US8273348B2 (en)	2006-12-21	2012-09-25	Novozymes A/S	Lipase variants for pharmaceutical use
US20090130063A1 (en) *	2007-11-15	2009-05-21	Solvay Pharmaceuticals Gmbh	Process for separating and determining the viral load in a pancreatin sample
CN101889084A (zh)	2007-12-04	2010-11-17	诺维信公司	供药学应用的蛋白酶变体
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
GB2465814B (en) *	2008-06-19	2011-10-26	Tarig Sayed Mustafa Arbab	Method,composition and device for the treatment of enzymes and saccharides disorders
US9320780B2 (en)	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) *	2008-06-26	2009-12-31	Fallon Joan M	Methods and compositions for the treatment of symptoms of complex regional pain syndrome
ES2732453T3 (es)	2008-07-01	2019-11-22	Curemark Llc	Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en)	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en)	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
CA3050530A1 (fr)	2009-01-06	2010-07-15	Galenagen, Llc	Compositions et procedes pour le traitement ou la prevention d'infections par staphylococcus aureus et pour l'eradication ou la reduction de staphylococcus aureus sur des surfaces
JP2012514604A (ja)	2009-01-06	2012-06-28	キュレロンリミテッドライアビリティカンパニー	大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
RU2400245C1 (ru) *	2009-04-02	2010-09-27	Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод"	Средство для контроля уровня гликемии и профилактики сосудистых осложнений у больных с нарушениями углеводного обмена и сахарным диабетом типа 2
US9056050B2 (en) *	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
JP2013525488A (ja) *	2010-05-03	2013-06-20	アプタリスファーマリミテッド	消化酵素混合物を含有するパンクレアチンを含むマイクロペレット組成物
MX362974B (es)	2011-04-21	2019-02-28	Curemark Llc	Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
US8268305B1 (en)	2011-09-23	2012-09-18	Bio-Cat, Inc.	Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2013155476A1 (fr) *	2012-04-12	2013-10-17	Integrative Enzymatics, Inc.	Composition et procédé pour moduler des molécules inflammatoires avec l'amylase
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
AU2018250823A1 (en)	2017-04-10	2019-10-17	Curemark, Llc	Compositions for treating addiction
SG11202002118XA (en) *	2017-09-19	2020-04-29	Univ Meiji	Method for developing organ that lacks specific functional cell
CN109142728A (zh) *	2018-09-04	2019-01-04	深圳市鸿美诊断技术有限公司	一种定量测定粪便中胰弹性蛋白酶1的试剂盒及其应用
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3803305A (en) *	1962-12-28	1974-04-09	Rolland A Lab	Process for obtaining extracts from pancreas
DE2512746C3 (de)	1975-03-22	1980-04-24	Kali-Chemie Pharma Gmbh, 3000 Hannover	Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
SU908352A1 (ru) *	1980-02-11	1982-02-28	Винницкий Областной Госпиталь Для Инвалидов Отечественной Войны	Способ лечени гнойных ран
DE4203315A1 (de)	1991-02-14	1992-08-20	Kali Chemie Pharma Gmbh	Verfahren zur gewinnung von pankreatin
US5614224A (en) *	1995-04-20	1997-03-25	Womack; Rick W.	Nutritional supplement for diabetics
EP1162995B1 (fr) *	1999-03-17	2003-06-04	Solvay Pharmaceuticals GmbH	Enzymes pour le traitement du diabete mellitus de type i

2000
- 2000-03-15 EP EP00925114A patent/EP1162995B1/fr not_active Expired - Lifetime
- 2000-03-15 RU RU2001126526/14A patent/RU2268065C2/ru not_active IP Right Cessation
- 2000-03-15 WO PCT/EP2000/002261 patent/WO2000054799A2/fr not_active Ceased
- 2000-03-15 PL PL350627A patent/PL199180B1/pl unknown
- 2000-03-15 HU HU0200556A patent/HUP0200556A3/hu unknown
- 2000-03-15 TR TR2001/02784T patent/TR200102784T2/xx unknown
- 2000-03-15 NZ NZ514826A patent/NZ514826A/en unknown
- 2000-03-15 ES ES00925114T patent/ES2194720T3/es not_active Expired - Lifetime
- 2000-03-15 PT PT00925114T patent/PT1162995E/pt unknown
- 2000-03-15 DK DK00925114T patent/DK1162995T3/da active
- 2000-03-15 CN CNB008049998A patent/CN1221284C/zh not_active Expired - Lifetime
- 2000-03-15 CZ CZ20013345A patent/CZ20013345A3/cs unknown
- 2000-03-15 AU AU43950/00A patent/AU773930B2/en not_active Expired
- 2000-03-15 BR BR0009012-3A patent/BR0009012A/pt not_active Application Discontinuation
- 2000-03-15 AT AT00925114T patent/ATE242003T1/de not_active IP Right Cessation
- 2000-03-15 DE DE10012095A patent/DE10012095A1/de not_active Withdrawn
- 2000-03-15 CA CA2367355A patent/CA2367355C/fr not_active Expired - Lifetime
- 2000-03-15 JP JP2000604871A patent/JP4938174B2/ja not_active Expired - Lifetime
- 2000-03-15 HK HK02106155.6A patent/HK1044477B/zh unknown
- 2000-03-15 SK SK1285-2001A patent/SK284677B6/sk unknown
- 2000-03-15 DE DE50002450T patent/DE50002450D1/de not_active Expired - Lifetime
2001
- 2001-08-28 ZA ZA200107110A patent/ZA200107110B/xx unknown
- 2001-09-17 US US09/953,450 patent/US7122357B2/en not_active Expired - Lifetime
- 2001-09-17 NO NO20014507A patent/NO20014507D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0009012A (pt)	2001-12-26
JP2002539173A (ja)	2002-11-19
HUP0200556A2 (en)	2002-06-29
AU4395000A (en)	2000-10-04
PL199180B1 (pl)	2008-08-29
EP1162995B1 (fr)	2003-06-04
PT1162995E (pt)	2003-08-29
ZA200107110B (en)	2002-10-30
NZ514826A (en)	2003-08-29
SK12852001A3 (sk)	2002-02-05
HK1044477B (zh)	2006-02-03
DK1162995T3 (da)	2003-06-23
NO20014507L (no)	2001-09-17
DE10012095A1 (de)	2000-09-21
CN1343126A (zh)	2002-04-03
PL350627A1 (en)	2003-01-27
CA2367355C (fr)	2012-06-05
EP1162995A2 (fr)	2001-12-19
DE50002450D1 (de)	2003-07-10
HK1044477A1 (en)	2002-10-25
TR200102784T2 (tr)	2002-04-22
RU2268065C2 (ru)	2006-01-20
HUP0200556A3 (en)	2006-06-28
US7122357B2 (en)	2006-10-17
CZ20013345A3 (cs)	2002-01-16
WO2000054799A3 (fr)	2001-04-26
ES2194720T3 (es)	2003-12-01
ATE242003T1 (de)	2003-06-15
CA2367355A1 (fr)	2000-09-21
US20020061302A1 (en)	2002-05-23
JP4938174B2 (ja)	2012-05-23
WO2000054799A2 (fr)	2000-09-21
CN1221284C (zh)	2005-10-05
NO20014507D0 (no)	2001-09-17
AU773930B2 (en)	2004-06-10

Publication	Publication Date	Title
SK12852001A3 (sk)	2002-02-05	Liečivo na liečenie diabetu
ES2302702T3 (es)	2008-08-01	Composicion farmaceutica que comprende una combinacion de metformina y glibenclamida.
JP5877902B2 (ja)	2016-03-08	バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用
JP5932878B2 (ja)	2016-06-08	血糖降下作用増強剤
JP2016000756A (ja)	2016-01-07	メトホルミン及びｄｐｐ−４阻害剤又はｓｇｌｔ−２阻害剤を含む医薬組成物
KR101493016B1 (ko)	2015-02-12	중약 조성물의 새로운 용도
CN101822658A (zh)	2010-09-08	半胱胺用于治疗高胆固醇血症和糖尿病并发症
CZ265199A3 (cs)	2000-02-16	Použití inhibitorů gastrointestinální lipasy
EP4523683A1 (fr)	2025-03-19	Compositions et méthodes de traitement de l'épilepsie
Mischler et al.	1982	Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis
CN111840112B (zh)	2021-07-20	鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
EP2841077B1 (fr)	2021-09-15	Compositions de fibres alimentaires pour le traitement d'une maladie métabolique
CN1127637A (zh)	1996-07-31	含有蚕粉末为有效成分的降血糖剂及其制造方法
AU776376B2 (en)	2004-09-09	Remedies for hyperammonemia
GB2468629A (en)	2010-09-15	Therapeutic uses of a composition comprising an amylase, a lipase and a protease
MXPA01008776A (en)	2002-05-09	Medicament for treating diabetes
EP4522133B1 (fr)	2026-01-14	Compositions et méthodes de traitement de l'épilepsie
CN104906115A (zh)	2015-09-16	一种二甲双胍格列喹酮复方缓释片及制备方法
US4562071A (en)	1985-12-31	Method of treating diabetic nephropathy
US20040176457A1 (en)	2004-09-09	Novel NIDDM regimen
TW202527911A (zh)	2025-07-16	用於治療猝睡症的化合物
CN119331778A (zh)	2025-01-21	一种用于辅助治疗糖尿病的乳酸菌组合物及复合乳酸菌益生菌剂和应用
CN117298154A (zh)	2023-12-29	一种治疗糖尿病胃轻瘫的中药组合物及制备方法
CA2636864A1 (fr)	2009-12-19	Methode, composition et dispositif de traitement de l'inactivite ou du dysfonctionnement de l'activite de l'amylase associes a des maladies basees sur des saccharides (surtout despolysaccharides)
WO2004075660A1 (fr)	2004-09-10	Aliment et medicament contenant de la gelee royale